Hypertension Webcasts

What is the most effective way to manage hypertension? In the following Novartis-sponsored webcasts, the expert panels explore how hypertension management can be optimised before delving into the available real-world and clinical trial data.

Optimising management of hypertension: use of CCBs vs. ARBs and use of CCB/ARB combination therapy

In a heterogeneous patient population like that seen in hypertension, it is essential that treatment is assessed and optimised. In this fascinating webcast, Professor Luis M Ruilope and Professor Rainer Düsing explore the roles of ARBs, CCBs and combination therapy in managing hypertension.


Optimising management of hypertension: use of CCBs vs. ARBs and use of CCB/ARB combination therapy. In part one of this webcast, Professor Ruilope explores the optimisation of hypertension management addressing the roles of different therapeutic classes and the importance of treatment adherence.


Optimising management of hypertension: use of CCBs vs. ARBs and use of CCB/ARB combination therapy. In part 2 of the webcast, Professor Düsing takes a deeper look at CCB and ARB therapies in hypertension management with an initial focus on the situation in China.


Optimising management of hypertension: use of CCBs vs. ARBs and use of CCB/ARB combination therapy. In the final part of the session, Professors Ruilope and Düsing answer questions from the webcast audience.

Key learnings from real-world evidence and randomised controlled trials in the treatment of hypertension

What is the difference between a real-world study and a randomised controlled trial (RCT) and what data have they provided for the management of hypertension? During this webcast, Professor Luis M Ruilope and Professor Rainer Düsing discuss these topics and provide their own insights.


Key learnings from real-world evidence and randomised controlled trials in the treatment of hypertension. In part one of this webcast, Professor Düsing addresses the meaning of real-world evidence and compares it to data from RCTs.


Key learnings from real-world evidence and randomised controlled trials in the treatment of hypertension. Professor Ruilope takes over for part 2 of the webcast where he offers a more detailed look at the available real-world and RCT data.


Key learnings from real-world evidence and randomised controlled trials in the treatment of hypertension. In the final part of the webcast, Professor Ruilope and Professor Düsing address questions from the webcast audience.

References